1-20 of 37
Sort by
News

Mid-July 2022 Data Stream

Free
Published: 2022
Abstract
Mid-July 2022
View News titled, Mid-July 2022 Data Stream
News

Subcutaneous Versus IV Daratumumab May Be a Preferred Treatment Choice in Patients With R/R MM

Free
Brandon May
Published: 2022
Abstract
Mid-July 2022
View News titled, Subcutaneous Versus IV Daratumumab May Be a Preferred Treatment Choice in Patients With R/R MM
News

Majority of Oncologists Reported Sexual Harassment in Past Year

Free
Leah Lawrence
Published: 2022
Abstract
Mid-July 2022
View News titled, Majority of Oncologists Reported Sexual Harassment in Past Year
News

Switching to Nonacog Beta Pegol Reduces Bleeding Rates in Patients With Hemophilia B

Free
Brandon May
Published: 2022
Abstract
Mid-July 2022
View News titled, Switching to Nonacog Beta Pegol Reduces Bleeding Rates in Patients With Hemophilia B
News

Greater AP Support May Mitigate Burnout Among Hematologists and Oncologists

Free
Brandon May
Published: 2022
Abstract
Mid-July 2022
View News titled, Greater AP Support May Mitigate Burnout Among Hematologists and Oncologists
News

Whole-Genome Sequencing Offers Insight Into Lymphoma Resistance to CAR T-Cell Therapy

Free
Brandon May
Published: 2022
Abstract
Mid-July 2022
View News titled, Whole-Genome Sequencing Offers Insight Into Lymphoma Resistance to CAR T-Cell Therapy
News

PI3K Inhibitor Approvals to Require Randomized Data

Free
Published: 2022
Abstract
Mid-July 2022
View News titled, PI3K Inhibitor Approvals to Require Randomized Data
News

Data-Driven Initiative Aims to Reduce Health Care Disparities

Free
Published: 2022
Abstract
Mid-July 2022
View News titled, Data-Driven Initiative Aims to Reduce Health Care Disparities
News

Medical Malls of America

Free
Published: 2022
Abstract
Mid-July 2022
View News titled, Medical Malls of America
News

HHS Challenges Health Care to Combat Climate Change

Free
Published: 2022
Abstract
Mid-July 2022
View News titled, HHS Challenges Health Care to Combat Climate Change
News

NK Cell Therapies Battle Hematologic Malignancies

Free
Published: 2022
Abstract
Mid-July 2022
View News titled, NK Cell Therapies Battle Hematologic Malignancies
News

Refill at the Global Pharmacy?

Free
Mary Ellen Schneider
Published: 2022
Abstract
Mid-July 2022 As drug prices climb, some countries look outside their borders for more affordable access to essential medicines.
View News titled, Refill at the Global Pharmacy?
News

Have a Little (Self)-Compassion

Free
Published: 2022
Abstract
Mid-July 2022
View News titled, Have a Little (Self)-Compassion
News

AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation

Free
Tess Stafford
Published: 2022
Abstract
Mid-July 2022
View News titled, AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation
News

Addition of Ibrutinib to Standard Therapy Improves PFS in Older Patients With MCL

Free
Deborah Levenson
Published: 2022
Abstract
Mid-July 2022
View News titled, Addition of Ibrutinib to Standard Therapy Improves PFS in Older Patients With MCL
News

Anti-Coagulation Therapy Compliance Poor in Cancer-Associated VTE

Free
Katie Robinson
Published: 2022
Abstract
Mid-July 2022
View News titled, Anti-Coagulation Therapy Compliance Poor in Cancer-Associated VTE
News

Venetoclax Combination Therapy Works Better in Some AML Subtypes Than Others

Free
Thomas R. Collins
Published: 2022
Abstract
Mid-July 2022
View News titled, Venetoclax Combination Therapy Works Better in Some AML Subtypes Than Others
News

Elranatamab Results in 61% ORR in Patients With R/R MM in Phase II Study

Free
Katie Robinson
Published: 2022
Abstract
Mid-July 2022
View News titled, Elranatamab Results in 61% ORR in Patients With R/R MM in Phase II Study
News

Women Underrepresented as Authors in Prestigious Cancer Trials

Free
Ruth Jessen Hickman, MD
Published: 2022
Abstract
Mid-July 2022
View News titled, Women Underrepresented as Authors in Prestigious Cancer Trials
News

Glofitamab Produces Durable Responses in DLBCL

Free
Thomas R. Collins
Published: 2022
Abstract
Mid-July 2022
View News titled, Glofitamab Produces Durable Responses in DLBCL